
Rheumatologist | Assistant Professor | University of Illinois, Chicago Cofounder @alwaysraas @officialgyfr
Chicago, IL
Joined March 2020
- Tweets59
- Following175
- Followers174
- Likes50
2026 FDA approvals in rheum, presented by Dr. Jeong Min Yu (FDA) at #ACR26: Brepocitinib: adult DM (JAK/TYK2) Tildrakizumab: adult PsA
Anifrolumab SC: SLE
Guselkumab: slows structural damage in PsA Peds: secukinumab AS ≥12 y, risankizumab PsA ≥6 y
#ACRambassador
New FDA safety label changes to know:
JAKi: hypoglycemia in diabetes
Tofacitinib: PML, fractures
Belimumab: SJS/TEN
Bisphosphonates: atypical non-femoral fractures
Oral MTX: deaths from daily-dosing errors
Dr. Karmela Kim Chan (FDA) #ACR26 #ACRambassador
Which AI tool can you trust for rheum questions?
5 platforms vs 60 ACR/EULAR-based scenarios
Guideline concordance: 75–91%
Hallucinations: 3.8–18.1%
0 of 5 error-free (dosing, outdated tx, screening)
AI output = a draft, not a decision
@ACRheum #ACR26 #ACRambassador Ab#0869
Axi Patel, MD retweeted
And the #ACR26 Knowledge Bowls winners are... the CAR-Titans from KIMS Hospitals, who rose to the occasion and successfully defended their 2025 title! 🏆
Congratulations to the team on your second Knowledge Bowl victory. Think you can take them on in 2027? Start training now! 🧠
#Rheumatology #KnowledgeBowl
⚖️ #ACR26 plenary (McCormick et al., RISE registry): in RA/PsA patients starting semaglutide or tirzepatide, each 5% weight loss was linked to better RAPID3 and 14% higher odds of meaningful gain. Mean loss 6.9% at 12 mo. @ACRheum #ACRambassador
Great to see ACR and OpenEvidence teaming up to put trusted patient education resources in clinicians' hands. 👏 #ACR26 @ACRheum #ACRambassador
📰 Newsflash! Yesterday during the ACR Convergence Opening Session, ACR President William Harvey, MD, MSc, FACR, announced a new collaboration between the ACR and OpenEvidence. This relationship aims to strengthen the connection between evidence-based information, patient education, and informed participation in care by giving rheumatologists, primary care providers, and other specialists managing rheumatic conditions the ability to access trusted, evidence-based ACR patient education resources through OpenEvidence. Read more → acr.tw/4j5nRNq
2
60
Dermatomyositis at the #ACR26 Year in Review (Dr. Liana Fraenkel): brepocitinib (oral TYK2/JAK1) is now FDA approved. At 30 mg, 54% reached moderate response on ≤2.5 mg prednisone vs 27% placebo. Mind the boxed infection warning and JAK precautions. @ACRheum #ACRambassador
2
135
Axi Patel, MD retweeted
Have you tried Ask ACR yet? Our new virtual assistant is here to help with any and all questions about ACR Convergence and is now available on any ACR Convergence page on rheumatology.org! Check it out → rheumatology.org/ask-acr #ACR26
Axi Patel, MD retweeted
Over the next several days, #ACR26 participants from around the world will delve into recent breakthroughs in the foundational science and clinical care of rheumatology, as well as new developments in medical education and more. Read the exciting details in ACR Convergence Today → acr.tw/4BKmJ9v
Excited to be joining the #ACR26 Social Media Ambassador team! Looking forward to bringing you the latest from ACR Convergence 2026
#ACRambassador
Meet the ACR Social Media Ambassadors! Follow along as these rheumatology social media stars get ready for ACR Convergence 2026. Discover their must-see sessions, join them at the meeting experience, and get a first-hand look at what the #rheum community is all about! Find and follow them here → rheumatology.org/social-medi…
#ACR26 #ACRambassador
Axi Patel, MD retweeted
🆕 Secrets & Pearls of Rheumatology at #ACR25 | Part 1 by @Janetbirdope
🖐️ Cutaneous Pathology SLE/DM
🧴 Tips for SLE
💪 Cancer Screening in Myositis
🩸 Laboratory Testing
🥶 Raynaud's / Scleroderma
👀 Sjogrens Disease
#RheumX #Lupus #Myositis
#Scleroderma #Sjogrens
Axi Patel, MD retweeted
Panelists will examine how to best deliver rheumatology care in the face of workforce challenges during an #ACR25 session.
🔗 Learn more → acr.tw/4np2o0Y
Axi Patel, MD retweeted
⚠️ Drug–Drug Interactions Alert! And renal remarks!
💊 Key warnings:
Tizanidine + CYP1A2 inhibitors ❌ Avoid
Voclosporin + CYP3A inhibitors ❌ Avoid
Tofacitinib/CyA/Tacrolimus + CYP3A inhibitors → ⚙️ Adjust
🕵🏻♀️vigilance prevents toxicity!
#ACR25 #ACR25ambassador @ACRheum
HCQ levels matter more than the dose. Let’s individualize, not generalize!
#ACR25 #ACRambassador @ACRheum
1
260
🩺 Empowering Patients Through Health Literacy
• Poor literacy fuels fear & misinformation
• Education builds trust & better outcomes
• Meet patients where they are
• Stories > stats: narratives change beliefs
• Clinicians online can counter myths
#ACR25 #ACRambassador
Axi Patel, MD retweeted
And the winner is...CAR-Titans @kimshospitals! Congratulations on dominating the #ACR25 #ACRKnowledgeBowl this year + taking home the Team Spirit Award too! 🏆📣🎉
Axi Patel, MD retweeted
The exciting final round of the #ACRKnowledgeBowl takes place TODAY at 1:00 PM CT in W375C! #ACR25 in-person attendees—join us to see which team will be crowned the 2025 ACR Knowledge Bowl Champion. 🏆 🏆 🏆
Will it be Metrotrexate @metrohealthCLE, CAR-Titans @kimshospitals, Stiff Competition @UMNews, or The ANCA-Teers @GeisingerHealth? 🤔Don’t miss it!
Axi Patel, MD retweeted
Journal Club with the editors of A&R and ARD at #ACR25
📅 Today! Monday, Oct 27, 1:00-2:00 PM, Room W185A-D
Hear from Dr. Lakin about her recent study published in A&R:
👉 Skin Biopsies Enhance Prediction of Clinical Trajectory in Diffuse Cutaneous Systemic Sclerosis
Axi Patel, MD retweeted
⭐ #ACR25 poster spotlight: Allyson Covello, MD, shares insight into the poster Patient Portal Awareness and Utilization Across Diverse Rheumatology Populations.
🔗 Learn more → acr.tw/43xwsAl




























